JoinClinicalTrials.com

• Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

  NCT02834013

  Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
  Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer

  NCT01344837

  Conditions:   Endometrial Serous Adenocarcinoma;   Stage I Uterine Corpus Cancer;   Stage II Uterine Corpus Cancer;   Stage III Uterine Corpus Cancer;   Stage IV Uterine Corpus Cancer
  Interventions:   Other: Diagnostic Laboratory Biomarker Analysis;   Other: Immunohistochemistry Staining Method;   Other: Medical Chart Review;   Genetic: Microarray Analysis;   Other: Study of Socioeconomic and Demographic Variables;   Genetic: Western Blotting
  Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
  Not yet recruiting
• DCE MRI in Patients With Pancreatic Cancer

  NCT02070705

  Conditions:   Healthy Subject;   Hereditary Pancreatic Carcinoma;   Pancreatic Adenocarcinoma;   Pancreatic Intraductal Papillary Mucinous Neoplasm
  Interventions:   Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging;   Drug: Ferumoxytol
  Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI);   National Institute for Biomedical Imaging and Bioengineering (NIBIB)
  Recruiting
• The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma

  NCT04076514

  Condition:   Papillary Thyroid Cancer
  Intervention:   Procedure: central neck dissection
  Sponsor:   Assiut University
  Recruiting
• Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation

  NCT04129411

  Conditions:   Papillary Thyroid Cancer;   Papillary Thyroid Microcarcinoma
  Intervention:   Device: RFA
  Sponsor:   Mayo Clinic
  Not yet recruiting
• Active Surveillance of Papillary Thyroid Microcarcinoma

  NCT02952612

  Condition:   Thyroid Cancer, Papillary
  Intervention:  
  Sponsor:   Dong Jun Lim
  Recruiting
• The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma

  NCT02418390

  Condition:   Thyroid Cancer, Papillary
  Intervention:   Procedure: prophylactic central lymph node dissection
  Sponsor:   Seoul National University Hospital
  Recruiting
• Studies on Tumors of the Thyroid

  NCT00001160

  Conditions:   Hurthle Cell Thyroid Cancer;   Tall Cell Variant Thyroid Cancer;   Follicular Thyroid Cancer;   Thyroid Cancer;   Papillary Thyroid Cancer
  Intervention:  
  Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  Recruiting
• Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial

  NCT03753919

  Conditions:   Metastatic Thyroid Papillary Carcinoma;   Metastatic Thyroid Follicular Carcinoma;   Metastatic Thyroid Cancer
  Interventions:   Drug: Durvalumab;   Drug: Tremelimumab
  Sponsors:   Grupo Espanol de Tumores Neuroendocrinos;   MFAR
  Recruiting
• Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer

  NCT03506048

  Conditions:   Differentiated Thyroid Gland Carcinoma;   Thyroid Gland Follicular Carcinoma;   Thyroid Gland Papillary Carcinoma
  Intervention:   Drug: Lenvatinib
  Sponsors:   Emory University;   Eisai Inc.
  Recruiting
• Evaluation of Accuracy of One-Step Nucleic Acid Amplification (OSNA) in Diagnosis of Lymph Node Metastases of Papillary Thyroid Carcinoma

  NCT03889769

  Conditions:   Papillary Thyroid Cancer;   Lymph Node Metastases
  Intervention:   Diagnostic Test: OSNA test
  Sponsor:   University of Cagliari
  Recruiting
• Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

  NCT03630120

  Conditions:   Thyroid Cancer;   Thyroid Cancer, Medullary;   Differentiated Thyroid Cancer;   Papillary Thyroid Cancer;   Follicular Thyroid Cancer;   Poorly Differentiated Thyroid Gland Carcinoma
  Interventions:   Drug: Lenvatinib;   Drug: Sorafenib;   Drug: Cabozantinib;   Drug: Vandetanib
  Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
  Recruiting
• Effectiveness of Intraoperative Neuromonitoring of External Branch of Superior Laryngeal Nerve During Thyroid Surgery

  NCT03773120

  Condition:   Carcinoma, Papillary, Follicular
  Intervention:   Device: Using Neuromonitoring to find EBSLN
  Sponsor:   Seoul National University Hospital
  Recruiting
• High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery

  NCT02757859

  Conditions:   Acinar Cell Carcinoma;   Ampulla of Vater Adenocarcinoma;   Cholangiocarcinoma;   Duodenal Adenocarcinoma;   Pancreatic Adenocarcinoma;   Pancreatic Ductal Adenocarcinoma;   Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type;   Periampullary Adenocarcinoma
  Interventions:   Procedure: Pancreatectomy;   Other: Lavage
  Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
  Recruiting
• Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

  NCT03037385

  Conditions:   RET-altered Non Small Cell Lung Cancer;   Medullary Thyroid Cancer;   RET-altered Papillary Thyroid Cancer;   RET-altered Colon Cancer;   RET-altered Solid Tumors;   Lung Neoplasm;   Carcinoma, Non-Small-Cell Lung;   Thyroid Diseases;   Thyroid Neoplasm;   Thyroid Cancer, Papillary;   Carcinoma, Neuroendocrine;   Respiratory Tract Neoplasms;   Thoracic Neoplasms;   Neoplasms by Site;   Neoplasms;   Lung Diseases;   Respiratory Tract Disease;   Carcinoma, Bronchogenic;   Bronchial Neoplasms;   Endocrine System Diseases;   Endocrine Gland Neoplasm;   Head and Neck Neoplasms;   Adenocarcinoma, Papillary;   Adenocarcinoma;   Carcinoma;   Neoplasms, Glandular and Epithelial;   Neoplasms by Histologic Type;   Neuroendocrine Tumors;   Neuroectodermal Tumors;   Neoplasms, Germ Cell and Embryonal;   Neoplasms, Nerve Tissue;   Colonic Neoplasms;   Colorectal Neoplasms;   Intestinal Neoplasms;   Gastrointestinal Neoplasms;   Digestive System Neoplasm;   Digestive System Disease;   Gastrointestinal Disease;   Colonic Diseases;   Intestinal Disease
  Intervention:   Drug: pralsetinib (BLU-667)
  Sponsor:   Blueprint Medicines Corporation
  Recruiting
• A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.

  NCT03469011

  Condition:   Papillary Thyroid Cancer
  Intervention:   Drug: Imatinib Oral Tablet
  Sponsors:   AHS Cancer Control Alberta;   Alberta Cancer Foundation
  Recruiting
• Central Cervical Dissection for Clinical Node Negative Papillary Thyroid Carcinoma

  NCT03813173

  Condition:   Lymph Node Metastases
  Intervention:   Procedure: lymph node dissection
  Sponsor:   Zhejiang University
  Not yet recruiting
• the Dissection of Lymph Node Posterior to Right Recurrent Laryngeal Nerve for Papillary Thyroid Carcinoma

  NCT03813706

  Condition:   Lymph Node Metastases
  Intervention:   Procedure: lymph node dissection
  Sponsor:   Zhejiang University
  Not yet recruiting
• Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer

  NCT03300284

  Condition:   Thyroid Cancer
  Intervention:   Behavioral: Questionnaires
  Sponsor:   Memorial Sloan Kettering Cancer Center
  Recruiting
• Deciding on Active Surveillance or Surgery for Primary Management of Low Risk Papillary Thyroid Cancer

  NCT03271892

  Condition:   Thyroid Cancer Stage I
  Intervention:  
  Sponsors:   University Health Network, Toronto;   Ontario Ministry of Health and Long Term Care;   Canadian Cancer Society Research Institute (CCSRI)
  Recruiting
• Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer.

  NCT03830242

  Conditions:   Positron-Emission Tomography;   Lymph Node Metastases;   Thyroid Cancer
  Interventions:   Diagnostic Test: ^{18F-FDG PET/CT dynamic scan;   Diagnostic Test: B-ultrasonography
  Sponsor:   Fifth Affiliated Hospital, Sun Yat-Sen University
  Recruiting}
• A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

  NCT01130519

  Conditions:   HLRCC;   Sporadic Papillary Renal Cell Cancer
  Interventions:   Drug: Bevacizumab;   Drug: Erlotinib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer

  NCT02138214

  Conditions:   Stage I Papillary Thyroid Cancer;   Stage II Papillary Thyroid Cancer;   Stage III Papillary Thyroid Cancer
  Interventions:   Procedure: Thyroidectomy;   Procedure: Central lymph node dissection;   Other: Quality-of-life assessment
  Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI);   National Institutes of Health (NIH)
  Recruiting
• Lenvatinib and Pembrolizumab in DTC

  NCT02973997

  Conditions:   Columnar Cell Variant Thyroid Gland Papillary Carcinoma;   Follicular Variant Thyroid Gland Papillary Carcinoma;   Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Stage III Differentiated Thyroid Gland Carcinoma AJCC v7;   Stage III Thyroid Gland Follicular Carcinoma AJCC v7;   Stage III Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IV Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IV Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7;   Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7;   Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7;   Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7;   Tall Cell Variant Thyroid Gland Papillary Carcinoma;   Thyroid Gland Hurthle Cell Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Lenvatinib;   Biological: Pembrolizumab
  Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
  Recruiting
• Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging

  NCT03470259

  Conditions:   Papillary Thyroid Cancer;   Lymph Node Metastases
  Interventions:   Drug: IV adminstration of EMI-137;   Device: Multispectral Fluorescence Reflectance Imaging;   Device: Spectroscopy
  Sponsors:   University Medical Center Groningen;   UMC Utrecht
  Recruiting
• Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

  NCT03914300

  Conditions:   Differentiated Thyroid Gland Carcinoma;   Follicular Variant Thyroid Gland Papillary Carcinoma;   Poorly Differentiated Thyroid Gland Carcinoma;   Progressive Thyroid Carcinoma;   Refractory Thyroid Gland Carcinoma;   Tall Cell Variant Thyroid Gland Papillary Carcinoma;   Thyroid Gland Follicular Carcinoma;   Thyroid Gland Hurthle Cell Carcinoma;   Thyroid Gland Papillary Carcinoma
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

  NCT02393690

  Conditions:   Metastatic Thyroid Gland Carcinoma;   Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Stage IV Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IV Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
  Interventions:   Radiation: Iodine I-131;   Other: Placebo;   Drug: Selumetinib
  Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
  Recruiting
• Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

  NCT02152995

  Conditions:   BRAF Gene Mutation;   Metastatic Thyroid Gland Carcinoma;   Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Refractory Thyroid Gland Carcinoma;   Stage IV Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IV Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7;   Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7;   Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
  Interventions:   Procedure: Computed Tomography;   Radiation: Iodine I 124;   Radiation: Iodine I-131;   Other: Laboratory Biomarker Analysis;   Other: Pharmacodynamic Study;   Procedure: Positron Emission Tomography;   Drug: Trametinib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

  NCT02495103

  Conditions:   Renal Cell Carcinoma;   Hereditary Leiomyomatosis and Renal Cell Cancer;   Papillary Renal Cell Carcinoma, Sporadic
  Interventions:   Drug: Vandetanib;   Drug: Metformin;   Drug: Vandetanib/Metformin
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Comparison Between Robotic, Endoscopic and Traditional Open Surgery in Thyroidectomy

  NCT03454477

  Conditions:   Endoscopy;   Robotics;   Thyroidectomy;   Papillary Thyroid Carcinoma
  Interventions:   Procedure: conventional open surgery;   Procedure: endoscopic thyroidectomy;   Device: robotic thyroidectomy
  Sponsor:   Fujian Medical University
  Recruiting
• A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

  NCT02019693

  Condition:   Kidney Cancer
  Intervention:   Drug: INC280
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Study on the Application of Convenient Foot-control Exhaust Method in Endoscopic Thyroidectomy

  NCT03411187

  Conditions:   Thyroid Cancer;   Papillary Thyroid Carcinoma;   Thyroidectomy;   Endoscopy
  Interventions:   Device: used of the Pressure adjustable foot-control method;   Device: direct exhaust
  Sponsor:   Bo Wang,MD
  Recruiting
• Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

  NCT02761057

  Conditions:   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Unresectable Renal Cell Carcinoma
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Drug: Savolitinib;   Drug: Sunitinib;   Drug: Sunitinib Malate
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  NCT03866382

  Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors

  NCT03899792

  Conditions:   Medullary Thyroid Cancer;   Infantile Myofibromatosis;   Infantile Fibrosarcoma;   Papillary Thyroid Cancer;   Soft Tissue Sarcoma
  Intervention:   Drug: LOXO-292
  Sponsor:   Loxo Oncology, Inc.
  Recruiting
• Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

  NCT02568267

  Conditions:   Breast Cancer;   Cholangiocarcinoma;   Colorectal Cancer;   Head and Neck Neoplasms;   Lymphoma, Large-Cell, Anaplastic;   Melanoma;   Neuroendocrine Tumors;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Papillary Thyroid Cancer;   Primary Brain Tumors;   Renal Cell Carcinoma;   Sarcomas;   Salivary Gland Cancers;   Adult Solid Tumor
  Intervention:   Drug: Entrectinib
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer

  NCT01109420

  Condition:   Non-Medullary Thyroid Cancer
  Intervention:  
  Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  Recruiting
• Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

  NCT04080284

  Conditions:   Endometrial Cancer;   Papillary Serous Endometrial Carcinoma;   Uterine Serous Carcinoma;   Endometrial Carcinoma;   Cancer of the Endometrium
  Intervention:   Drug: Niraparib
  Sponsors:   Northwell Health;   Tesaro, Inc.
  Not yet recruiting
• ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)

  NCT03685448

  Conditions:   Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma Type 1;   Papillary Renal Cell Carcinoma Type 2;   Chromophobe Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Xp11.2 Translocation-Related Renal Cell Carcinoma
  Intervention:   Drug: Cabozantinib
  Sponsor:   Australian and New Zealand Urogenital and Prostate Cancer Trials Group
  Recruiting